---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-035304"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:29:50.493345+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics Q3 2024 net loss $3.1M; cash $2.6M; AJ201 data expected year-end

## Summary
- Net loss of $3.1M ($1.92/share) vs net income of $0.5M in Q3 2023.
- Cash and equivalents $2.6M at Sep 30, 2024, down $2.3M from Q2 2024.
- R&D expenses $2.3M, up from $0.9M in prior year; G&A $0.8M down from $1.2M.
- Topline data from AJ201 Phase 1b/2a trial in SBMA expected around year-end 2024.
- IV Tramadol Phase 3 safety protocol finalized with FDA; study start subject to financing.

## SEC filing metadata
- accession: 0001437749-24-035304
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000143774924035304/0001437749-24-035304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000143774924035304/atxi20241114_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-035304
- JSON: https://secwatch.observer/filing/0001437749-24-035304.json
- Plain text: https://secwatch.observer/filing/0001437749-24-035304.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.